PDCD1 and non-small cell lung carcinoma: Clinically, the HDACi Vorinostat was evaluated in a phase I trial alongside the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab, demonstrating enhanced survival outcomes in patients with advanced or metastatic NSCLC 4.